Hepatology and Pancreatic Science

Impact of DAAS on resection of HCC on cirrhotic liver, outcome and prognosis

Abstract

El Sherif A*, Elgazar M, Sweed D, Ayoub I, Yassein T and Abo El Ella K

Hepatocellular Carcinoma (HCC) is one of the leading causes of death from cancer in the world. Direct-acting Antiviral (DAA) therapy has revolutionized the treatment of Hepatitis C Virus (HCV) infection, with very high rates of Sustained Virology Response (SVR) and an excellent safety profile. The procedures performed were: 22 cases done major RT hepatectomies (32.4%). 12 cases underwent Lt Lateral hepatectomy (17.6%) 34 cases underwent non anatomical resection (50%). Time of hepatic transection was performed is 192 min average range (135 to 250 min). The average blood loss was 825 ml (range 50-1600 ml).

The treatment approach for Hepatocellular Carcinoma (HCC) depends on the stage and extent of disease, the severity of the underlying liver disease, and the overall performance status of the patient.